DK39798A - Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs - Google Patents

Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs

Info

Publication number
DK39798A
DK39798A DK199800397A DK39798A DK39798A DK 39798 A DK39798 A DK 39798A DK 199800397 A DK199800397 A DK 199800397A DK 39798 A DK39798 A DK 39798A DK 39798 A DK39798 A DK 39798A
Authority
DK
Denmark
Prior art keywords
sulfinyl
benzimidazole
pyridinyl
progress
methyl
Prior art date
Application number
DK199800397A
Other languages
English (en)
Other versions
DK173431B1 (da
Inventor
Henriksen Kristian Lund
Kann Helle
Soerensen Karen Eichstedt
Pedersen Soeren Bols
Original Assignee
Gea Farmaceutisk Fabrik As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK39798(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gea Farmaceutisk Fabrik As filed Critical Gea Farmaceutisk Fabrik As
Priority to DK199800397A priority Critical patent/DK173431B1/da
Priority to TW088103837A priority patent/TW529951B/zh
Priority to US09/646,486 priority patent/US6391342B1/en
Priority to DK99907346T priority patent/DK1061920T3/da
Priority to TR2000/02696T priority patent/TR200002696T2/xx
Priority to AT99907346T priority patent/ATE218863T1/de
Priority to CZ20003458A priority patent/CZ291943B6/cs
Priority to ES99907346T priority patent/ES2177246T3/es
Priority to EA200000970A priority patent/EA002502B1/ru
Priority to CA002323536A priority patent/CA2323536C/en
Priority to PCT/DK1999/000137 priority patent/WO1999048498A1/en
Priority to NZ507115A priority patent/NZ507115A/xx
Priority to DE69901804T priority patent/DE69901804T2/de
Priority to AU27148/99A priority patent/AU744596B2/en
Priority to EP99907346A priority patent/EP1061920B1/en
Priority to PL342840A priority patent/PL192437B1/pl
Priority to HU0101178A priority patent/HU226580B1/hu
Priority to ARP990101230A priority patent/AR014753A1/es
Publication of DK39798A publication Critical patent/DK39798A/da
Priority to ZA200004757A priority patent/ZA200004757B/xx
Priority to IS5628A priority patent/IS2265B/is
Priority to NO20004667A priority patent/NO20004667L/no
Publication of DK173431B1 publication Critical patent/DK173431B1/da
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK199800397A 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs DK173431B1 (da)

Priority Applications (21)

Application Number Priority Date Filing Date Title
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
TW088103837A TW529951B (en) 1998-03-20 1999-03-12 Pharmaceutical composition comprising a 2- [[(2-pyridinyl) methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such pharmaceutical composition
PCT/DK1999/000137 WO1999048498A1 (en) 1998-03-20 1999-03-17 Pharmaceutical formulation comprising a 2- [[(2- pyridinyl) methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
AU27148/99A AU744596B2 (en) 1998-03-20 1999-03-17 Pharmaceutical formulation comprising a 2- (((2- pyridinyl) methyl) sulfinyl) benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
TR2000/02696T TR200002696T2 (tr) 1998-03-20 1999-03-17 Ülsere karşı aktifliği olan 2-[[(2-piridinil)metil] sulfinil] benzimidazol içeren farmasötik bileşim ve bu tip bir formülasyonun hazırlanması için bir işlem
AT99907346T ATE218863T1 (de) 1998-03-20 1999-03-17 Pharmazeutische formulierungen enthaltend ein 2(((2-pyridinyl)methyl)sulfinyl)benzimidazol mit antiulcus wirkung und verfahren zur herstellung solcher formulierungen
CZ20003458A CZ291943B6 (cs) 1998-03-20 1999-03-17 Farmaceutický prostředek
ES99907346T ES2177246T3 (es) 1998-03-20 1999-03-17 Formulacion farmaceutica que comprende un 2-((2-piridinil)metil)sulfinil)benzimidazol dotado de actividad antiulcerosa y procedimiento de preparacion de dicha formulacion.
EA200000970A EA002502B1 (ru) 1998-03-20 1999-03-17 Фармацевтическая лекарственная форма, включающая 2-[[(2-пиридинил) метил] сульфинил] бензимидазол, обладающий противоязвенной активностью, и способ изготовления такой лекарственной формы
CA002323536A CA2323536C (en) 1998-03-20 1999-03-17 Pharmaceutical formulation comprising a 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
US09/646,486 US6391342B1 (en) 1998-03-20 1999-03-17 Pharmaceutical formulation comprising a 2- [(2-pyridinyl) methyl] sulfinyl benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
NZ507115A NZ507115A (en) 1998-03-20 1999-03-17 Pharmaceutical formulation comprising a 2- [[(2- pyridinyl) methyl] sulfinyl] benzimidazole having anti-ulcer activity
DE69901804T DE69901804T2 (de) 1998-03-20 1999-03-17 Pharmazeutische formulierungen enthaltend ein 2[[(2-pyridinyl)methyl]sulfinyl]benzimidazol mit antiulcus wirkung und verfahren zur herstellung solcher formulierungen
DK99907346T DK1061920T3 (da) 1998-03-20 1999-03-17 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangsmåde til fremstilling af en sådan formulering
EP99907346A EP1061920B1 (en) 1998-03-20 1999-03-17 Pharmaceutical formulation comprising a 2[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
PL342840A PL192437B1 (pl) 1998-03-20 1999-03-17 Kompozycja farmaceutyczna do podawania doustnego zawierająca 2-[[(2-pirydynylo)metylo]sulfinylo]benzimidazol i sposób otrzymywania tej kompozycji
HU0101178A HU226580B1 (en) 1998-03-20 1999-03-17 Pharmaceutical formulation comprising a 2-[[(2-pyridinyl)methyl]sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
ARP990101230A AR014753A1 (es) 1998-03-20 1999-03-19 Formulacion farmaceutica que contiene un 2-[[(2-piridinil)metil]sulfinil] bencimidazol que tiene una actividad antiulcerosa, y un proceso para lapreparacion de dicha formulacion
ZA200004757A ZA200004757B (en) 1998-03-20 2000-09-08 Pharmaceutical formulation comprising A 2-[[(2-pyridinyl)methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation.
IS5628A IS2265B (is) 1998-03-20 2000-09-13 Lyfjablanda sem inniheldur 2-[[(2-pýridínýl)metýl]súlfínýl]bensimídasól með virkni gegn sármyndun og aðferð til að framleiða slíka blöndu
NO20004667A NO20004667L (no) 1998-03-20 2000-09-19 Farmasoytisk formulering omfattende et 2-[[(2-pyridinyl)metyl]sulfinyl]benzimidazol med anti-ulcusaktivitet, og en fremgangsmate for fremstilling av en slik formulering

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
DK39798 1998-03-20

Publications (2)

Publication Number Publication Date
DK39798A true DK39798A (da) 1999-09-21
DK173431B1 DK173431B1 (da) 2000-10-23

Family

ID=8093069

Family Applications (2)

Application Number Title Priority Date Filing Date
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
DK99907346T DK1061920T3 (da) 1998-03-20 1999-03-17 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangsmåde til fremstilling af en sådan formulering

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99907346T DK1061920T3 (da) 1998-03-20 1999-03-17 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangsmåde til fremstilling af en sådan formulering

Country Status (20)

Country Link
US (1) US6391342B1 (da)
EP (1) EP1061920B1 (da)
AR (1) AR014753A1 (da)
AT (1) ATE218863T1 (da)
AU (1) AU744596B2 (da)
CA (1) CA2323536C (da)
CZ (1) CZ291943B6 (da)
DE (1) DE69901804T2 (da)
DK (2) DK173431B1 (da)
EA (1) EA002502B1 (da)
ES (1) ES2177246T3 (da)
HU (1) HU226580B1 (da)
IS (1) IS2265B (da)
NO (1) NO20004667L (da)
NZ (1) NZ507115A (da)
PL (1) PL192437B1 (da)
TR (1) TR200002696T2 (da)
TW (1) TW529951B (da)
WO (1) WO1999048498A1 (da)
ZA (1) ZA200004757B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053918A1 (fr) 1998-04-20 1999-10-28 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU775995B2 (en) 1999-06-07 2004-08-19 Nycomed Gmbh Novel preparation and administration form comprising an acid-labile active compound
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004089333A2 (en) * 2003-02-28 2004-10-21 Cadila Healthcare Limited A stable benzimidazole formulation
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
BRPI0415242B8 (pt) * 2003-10-10 2021-05-25 Ethypharm Sa microgrânulos de liberação gradual contendo extrato de gingko biloba e o processo para fabricar estes
CA2552440A1 (en) * 2003-12-30 2005-07-21 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
ATE531361T1 (de) 2004-05-07 2011-11-15 Nycomed Gmbh Neue pharmazeutische dosierform und herstellungsverfahren
CA2570916C (en) * 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
KR20090033825A (ko) * 2005-12-16 2009-04-06 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 일라프라졸의 약제학적 조성물
WO2007100984A2 (en) * 2006-02-24 2007-09-07 Allergan, Inc. Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100239681A1 (en) * 2009-03-20 2010-09-23 Biokey, Inc. Controlled Release Particulates Containing Water-Insoluble Drug
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EP2319504A1 (en) * 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN103202820B (zh) * 2012-01-11 2016-03-30 浙江亚太药业股份有限公司 一种稳定的兰索拉唑肠溶胶囊及其制备方法
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
ES2024993A6 (es) 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
TW209174B (da) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
SE9200858L (sv) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
ES2087823B1 (es) 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E Formulacion de microgranulos gastroresistentes de omeprazol y su procedimiento de fabricacion.
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
CH687810A5 (de) 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
ATE262332T1 (de) 1995-09-21 2004-04-15 Pharma Pass Ii Llc Lansoprazolhaltige arzneizusammensetzung und herstellungsverfahren
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
PT101826A (pt) 1996-02-06 1997-09-30 Medinfar Produtos Farmaceutico Processo para a preparacao de microgranulos contendo omeprazole
WO1998040377A1 (en) 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose

Also Published As

Publication number Publication date
EA002502B1 (ru) 2002-06-27
IS5628A (is) 2000-09-13
NO20004667L (no) 2000-11-09
ES2177246T3 (es) 2002-12-01
HUP0101178A2 (hu) 2001-08-28
EP1061920B1 (en) 2002-06-12
CA2323536C (en) 2009-05-19
DE69901804D1 (de) 2002-07-18
PL342840A1 (en) 2001-07-16
NO20004667D0 (no) 2000-09-19
US6391342B1 (en) 2002-05-21
DE69901804T2 (de) 2002-12-12
NZ507115A (en) 2002-09-27
CA2323536A1 (en) 1999-09-30
AR014753A1 (es) 2001-03-28
IS2265B (is) 2007-07-15
DK1061920T3 (da) 2002-07-15
AU2714899A (en) 1999-10-18
CZ20003458A3 (cs) 2001-03-14
AU744596B2 (en) 2002-02-28
ZA200004757B (en) 2001-05-30
WO1999048498A1 (en) 1999-09-30
ATE218863T1 (de) 2002-06-15
DK173431B1 (da) 2000-10-23
EA200000970A1 (ru) 2001-02-26
CZ291943B6 (cs) 2003-06-18
PL192437B1 (pl) 2006-10-31
TR200002696T2 (tr) 2000-12-21
HU226580B1 (en) 2009-04-28
EP1061920A1 (en) 2000-12-27
TW529951B (en) 2003-05-01

Similar Documents

Publication Publication Date Title
DK39798A (da) Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
DK0984773T3 (da) Farmaceutisk formulering med omeprazol
DK0818454T3 (da) Benzimidazolderivater med antihistamin-aktivitet
NO20014096D0 (no) Fenyl- og pyridinylderivater
EE04597B1 (et) Esemete kuivpuhastuseade ja eseme kuivpuhastusmeetod
EE04631B1 (et) Meetod farmatseutilise ravimvormi aerosoolistamiseks ja pihustusseade
EE200200241A (et) Suhkurtõvevastane preparaat ja meetod
NO20016078D0 (no) Tiazol- og oksazol-derivater samt farmasöytisk anvendelse derav
DE60031119D1 (de) Richtbohrvorrichtung und -verfahren
IS5285A (is) Benzímídasól afleiður
TR200000534A3 (tr) Bir ilacin uygulanmasi için metot ve sistem
EE04344B1 (et) Telmisartaani polümorfid, meetodid nende valmistamiseks ja nende kasutamine ravimi valmistamiseks
EP1242076A4 (en) 2-BENZYL- AND 2-HETEROARYLBENZIMIDAZOLES AS NMDA / NR2B ANTAGONISTS
EE200200165A (et) Farmatseutiliselt toimivad sulfoonamiidi derivaadid
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
FI20000480A0 (fi) Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
DK1183251T3 (da) Indolylpiperidinderivater som antihistamin- og antiallergimidler
NO20015510D0 (no) Medikament for lokal påföring
NO994340D0 (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler samt nye forbindelser til anvendelse for dette formÕl
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
NO20005271L (no) Optisk aktive tetrahydrobenzindol-derivater
DK199900435U3 (da) Farmaceutisk præparat omfattende paroxetin-methansulfonat samt anvendelse heraf
NO20004816D0 (no) Ny farmasøytisk formulering
ATE266631T1 (de) Imidamid-derivate
DE59909479D1 (de) Imidamid-derivate

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PPF Opposition filed
PDQ Request for opposition withdrawn
PBP Patent lapsed

Country of ref document: DK